2185 — Shanghai Bio-heart Biological Technology Co Income Statement
0.000.00%
Last trade - 00:00- HK$453.72m
- HK$86.07m
Annual income statement for Shanghai Bio-heart Biological Technology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 23.6 | 340 | 409 | 228 | 187 |
| Operating Profit | -23.6 | -340 | -409 | -228 | -187 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -23.7 | -340 | -410 | -231 | -189 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -23.7 | -340 | -410 | -231 | -189 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -23.7 | -326 | -361 | -204 | -176 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.7 | -326 | -361 | -204 | -176 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.1 | -1.35 | -1.55 | -0.838 | -0.603 |